22 Nov Things You Need to Know About the Taxotere Lawsuit
Taxotere Chemotherapy Drug Maker’s Failure to Warn Class Action Lawsuit
Taxotere is an FDA approved drug used to treat some types of cancer and like all drugs, it has side effects. Though, this drug has some side effects that are irreversible and resulted in a class action lawsuit. This is a drug that has been used by approximately 2 million women in cancer treatment. It has been used in place of other chemotherapy drugs since it may shorten the duration of chemotherapy treatment.
This drug is used for specific types of cancer including breast, stomach and lung cancers. While these kinds of medicines are known for being toxic in order to kill cancer cells they all have some side effects. But Taxotere has at least one side effect when used that is permanent. This is a drug that can cause permanent Alopecia.
Taxotere Failure to Warn
One of the complaints lodged in the lawsuit is the manufacturer of the cancer drug Sanofi-Aventis failed to warn cancer patients of the side effect use of the drug could cause. The drug was approved by the U.S. Food and Drug Administration in 1996. At the time of approval possible permanent hair loss was not listed as a side effect. There was only a vague warning in the prescribing information and stated: “hair generally grows back.” The warning for this possibility did not appear in the warning for the drug until December 2015, though the label was changed in Canada in 2012. This came after there were lawsuits filed as early in Europe. The warning was changed as early as 2005 in Europe, but not in the United States or Canada.
The court documents show that over 1,000 permanent hair loss cases for Taxotere have been filed. This included the generic versions of the cancer drug docetaxel. The product liability case number MDL No. 2740 (Taxotere MDL). The cases have been consolidated and scheduled to begin in January 2019. Though there are currently settlement negotiations occurring between the defendants and plaintiffs.
May 15th, 2017 a pretrial order was directed by the court for both parties to submit a proposed order for a discovery schedule and dates.
Taxotere Class Action Deadline
The court has set several deadlines in this taxotere lawsuit against Sanofi-Aventis Pharmaceuticals. Some of these deadlines pertain to personal jurisdiction discovery including:
- May 17, 2017: A May 26th deadline was set after Sanofi-Aventis lawyers filed a motion to dismiss in a meeting with the defendants in the lawsuit.
- May 26, 2017: This is when plaintiffs were to serve personal jurisdiction discovery that is relevant after the motion to dismiss.
- June 2, 2017: The parties were set to meet again with served personal jurisdiction discovery.
- June 15, 2017: Defendants can submit any objections to foreign merits discovery.
- June 30, 2017: The defendants, Sanofi-Aventis in the case have the opportunity to respond and make objections to served personal jurisdiction discovery.
Further, the magistrate judge in the litigation of Taxotere planned to schedule a hearing to resolve differences for the jurisdictional discovery.